Search results for "Perch"

showing 10 items of 1084 documents

CCDC 244991: Experimental Crystal Structure Determination

2006

Related Article: C.Gerard, A.Mohamadou, J.Marrot, S.Brandes, A.Tabard|2005|Helv.Chim.Acta|88|2397|doi:10.1002/hlca.200590176

bis(mu~2~-tris(2-((2-Pyridylmethyl)amino)ethyl)amine)-bis(perchlorato-O)-tri-copper(ii) tetraperchlorate dihydrateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 722374: Experimental Crystal Structure Determination

2010

Related Article: C.Yuste, L.Canadillas-Delgado, A.Labrador, F.S.Delgado, C.Ruiz-Perez, F.Lloret, M.Julve|2009|Inorg.Chem.|48|6630|doi:10.1021/ic900599g

bis(mu~3~-246-tris(di-2-pyridylamine)-135-triazine)-triaqua-tri-copper(ii) hexaperchlorate dihydrateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 193550: Experimental Crystal Structure Determination

2003

Related Article: V.V.Pavlishchuk, S.V.Kolotilov, A.W.Addison, M.J.Prushan, D.Schollmeyer, L.K.Thompson, T.Weyhermuller, E.A.Goreshnik|2003|Dalton Trans.||1587|doi:10.1039/b300539a

bis(mu~3~-Hydroxo)-tetrakis(mu~2~-butane-23-dione monooximato)-bis(15-diamino-3-azapentane)-tetra-nickel(ii) diperchlorate monohydrateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 190465: Experimental Crystal Structure Determination

2003

Related Article: V.V.Pavlishchuk, S.V.Kolotilov, A.W.Addison, M.J.Prushan, D.Schollmeyer, L.K.Thompson, T.Weyhermuller, E.A.Goreshnik|2003|Dalton Trans.||1587|doi:10.1039/b300539a

bis(mu~3~-Hydroxo)-tetrakis(mu~2~-butane-23-dione monooximato)-bis(15-diamino-3-azapentane)-tetra-nickel(ii) diperchlorate monohydrateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 879928: Experimental Crystal Structure Determination

2013

Related Article: Albert Escuer, Gina Vlahopoulou, Francesc Lloret, Franz A. Mautner|2014|Eur.J.Inorg.Chem.||83|doi:10.1002/ejic.201300910

bis(mu~3~-hydroxo)-hexakis(mu~2~-([(6-methylpyridin-2-yl)methylidene]amino)oxidanide)-tris(mu~2~-perchlorato)-hexa-copper perchlorateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 1045981: Experimental Crystal Structure Determination

2015

Related Article: Michele Bedin, Alavi Karim, Marcus Reitti, Anna-Carin C. Carlsson, Filip Topić, Mario Cetina, Fangfang Pan, Vaclav Havel, Fatima Al-Ameri, Vladimir Sindelar, Kari Rissanen, Jürgen Gräfenstein, Máté Erdélyi|2015|Chemical Science|6|3746|doi:10.1039/C5SC01053E

bis(pyridine)iodonium perchlorateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 1965760: Experimental Crystal Structure Determination

2021

Related Article: Munirathnam Manda, Himanshu Arora, Arunava Sengupta, Shashi Kant, Francesc Lloret, Rabindranath Mukherjee|2021|New J.Chem.|45|16019|doi:10.1039/D1NJ01150B

bis{mu-N-[2-(dimethylamino)ethyl]-N-[(6-methylpyridin-2-yl)methyl]-beta-alaninato}-bis(methanol)-di-manganese diperchlorateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

Effects of statins, fibrates, rosuvastatin, and ezetimibe beyond cholesterol: the modulation of LDL size and subclasses in high-risk patients.

2007

Increasing evidence suggests that the quality-rather than just the quantity-of low-density lipoproteins (LDLs) exerts a great influence on cardiovascular risk. LDLs comprise multiple subclasses with discrete size and density, and different physicochemical composition, metabolic behaviors, and atherogenicity. Individuals generally cluster into 2 broad subgroups. Most have a predominance of large LDLs, and some have a higher proportion of small particles. Small, dense LDLs are good predictors of cardiovascular events and progression of coronary artery disease. Their predominance has been accepted as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Tre…

cardiovascular riskRiskStatinmedicine.drug_classHypercholesterolemiasubclassePharmacologyBioinformaticschemistry.chemical_compoundClofibric AcidEzetimibemedicineHumansPharmacology (medical)Cholesterol absorption inhibitorRosuvastatinRisk factorRosuvastatin CalciumNational Cholesterol Education ProgramSulfonamidessmall dense LDLfibrateCholesterolbusiness.industryAnticholesteremic AgentsstatinGeneral MedicineCholesterol LDLEzetimibeFluorobenzenesRosuvastatin CalciumPyrimidineschemistrydiabeteCardiovascular DiseasesAzetidineslipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase Inhibitorsbusinessrosuvastatinmedicine.drugAdvances in therapy
researchProduct

Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid…

2022

Proprotein convertase subtilisin/kexin type 9 (PCSK9), beyond regulating LDL cholesterol (LDL-c) plasma levels, exerts several pleiotropic effects by modulating lipid metabolism in extrahepatic cells such as macrophages. Macrophage cholesterol homeostasis depends on serum lipoprotein functions, including the HDL capacity to promote cell cholesterol efflux (CEC) and the serum capacity to promote cell cholesterol loading (CLC). The aim of this observational study was to investigate the effect of PCSK9 inhibitors (PCSK9-i) treatment on HDL-CEC and serum CLC in patients with familial hypercholesterolemia (FH). 31 genetically confirmed FH patients were recruited. Blood was collected and serum is…

cardiovascular riskSettore MED/09 - Medicina Internafamilial hypercholesterolemiaPCSK9 inhibitors cardiovascular risk cholesterol efflux capacity cholesterol loading capacity familial hypercholesterolemiaPCSK9 inhibitorsSettore BIO/14 - Farmacologiacholesterol loading capacityBiochemistry Genetics and Molecular Biology (miscellaneous)Molecular BiologyBiochemistrycholesterol efflux capacityPCSK9 inhibitors; cardiovascular risk; cholesterol efflux capacity; cholesterol loading capacity; familial hypercholesterolemiaFrontiers in molecular biosciences
researchProduct

Lipoprotein(a) Genotype Influences the Clinical Diagnosis of Familial Hypercholesterolemia

2023

: Background Evidence suggests that LPA risk genotypes are a possible contributor to the clinical diagnosis of familial hypercholesterolemia (FH). This study aimed at determining the prevalence of LPA risk variants in adult individuals with FH enrolled in the Italian LIPIGEN (Lipid Transport Disorders Italian Genetic Network) study, with (FH/M+) or without (FH/M-) a causative genetic variant. Methods and Results An lp(a) [lipoprotein(a)] genetic score was calculated by summing the number risk-increasing alleles inherited at rs3798220 and rs10455872 variants. Overall, in the 4.6% of 1695 patients with clinically diagnosed FH, the phenotype was not explained by a monogenic or polygenic cause …

cardiovascular risklipoprotein(a).familial hypercholesterolemia
researchProduct